ADC Therapeutics is a commercial-stage biotechnology company dedicated to delivering next-generation PBD-Based ADCs for those affected by cancer. With a deep understanding of ADC technology and of the oncology treatment landscape, ADC Therapeutics intends to address significant unmet medical needs and improve outcomes for those with difficult-to-treat cancers.
ADC Therapeutics.
Confronting cancer with the full potential of our science.
Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial) and the San Francisco Bay Area (CMC).
“Providing unique, targeted therapies for those in need isn’t just a priority, it’s a privilege.”
— Chris Martin, CEO and Cofounder, ADC Therapeutics
Our History
2011
ADC Therapeutics founded as a spin-off from Spirogen Ltd, which was founded in 2000 and was an early innovator in PBD-based ADC research
2015
ADC Therapeutics cofounder Chris Martin appointed CEO
2016
First patient enrolled in phase 1 clinical trial of lead investigational compound loncastuximab tesirine-lpyl, targeting CD19 in positive B-cell non-Hodgkin lymphoma
2019
First patient enrolled in phase 2 clinical trial of investigational compound camidanlumab tesirine, targeting CD25 in relapsed or refractory Hodgkin lymphoma
2020
Ron Squarer, former CEO of Array BioPharma, Inc, appointed Chairman of the Board
$267-million IPO with the NYSE
ticker “ADCT”
ticker “ADCT”
Announced pivotal phase 2 clinical trial of CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
Biologics license application (BLA) submission for CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
Biologics license application (BLA) acceptance with priority review for CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
2021
CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl receives FDA approval
2021
- April
CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl receives FDA approval
2020
- November
Biologics license application (BLA) acceptance with priority review for CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
- September
Biologics license application (BLA) submission for CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
- June
Announced pivotal phase 2 clinical trial of CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
- May
$267-million IPO with the NYSE ticker “ADCT”
- March
Ron Squarer, former CEO of Array BioPharma, Inc, appointed Chairman of the Board
2019
- October
First patient enrolled in phase 2 clinical trial of investigational compound camidanlumab tesirine, targeting CD25 in relapsed or refractory Hodgkin lymphoma
2016
- March
First patient enrolled in phase 1 clinical trial of lead investigational compound loncastuximab tesirine-lpyl, targeting CD19 in positive B-cell non-Hodgkin lymphoma
2015
- June
ADC Therapeutics cofounder Chris Martin appointed CEO
2011
- June
ADC Therapeutics founded as a spin-off from Spirogen Ltd, which was founded in 2000 and was an early innovator in PBD-based ADC research
ADC, antibody-drug conjugate; PBD, pyrrolobenzodiazepine.
Our Purpose
Our mission, vision, and values form the foundation of ADC Therapeutics and provide guidance for all future endeavors. These foundational pillars are also a meaningful expression of the company’s dedication to helping those with difficult-to-treat cancers.
Our Mission
We are confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.
Our Vision
We will transform what patients and their families can expect from cancer therapy.
Our Values
PATIENTS: Patients and their families are at the core of everything we do; they inspire our scientific creativity and innovation
CHARACTER: We are open, honest, trustworthy, and respectful in our words and actions
URGENCY: We operate with a sense of urgency in all that we do
PEOPLE: We encourage individuals to continually learn and grow so that everyone can work at their full potential
Our Leadership
and the Board of Directors
Partnering
At ADC Therapeutics, we are on a mission to confront cancer with the full potential of our science to bring unique, targeted therapies and hope to patients and their families. To help support this mission, we actively seek innovative collaborations and strategic business development opportunities.
To start the conversation about partnering with ADC Therapeutics, please contact us at partnering@adctherapeutics.com.
